{"id":"standard-dose-lamotrigine","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Rash (including Stevens-Johnson syndrome risk)"},{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Ataxia"},{"rate":"10-15","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Diplopia"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lamotrigine stabilizes neuronal membranes by blocking sodium channels in a use-dependent manner, which prevents repetitive neuronal firing. It also inhibits the release of glutamate, an excitatory neurotransmitter, through effects on calcium channels. These combined actions reduce abnormal electrical activity in the brain.","oneSentence":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:09:15.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Epilepsy (adjunctive and monotherapy)"},{"name":"Bipolar disorder maintenance treatment"},{"name":"Lennox-Gastaut syndrome"}]},"trialDetails":[{"nctId":"NCT03689114","phase":"PHASE4","title":"Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2021-05-10","conditions":"Epilepsies, Partial","enrollment":58},{"nctId":"NCT06488586","phase":"","title":"IV Ketamine Vs. in Esketamine for MDD TRD","status":"RECRUITING","sponsor":"Gustavo Vazquez","startDate":"2023-03-20","conditions":"Treatment Resistant Depression","enrollment":80},{"nctId":"NCT05450822","phase":"","title":"Precision Medicine in the Treatment of Epilepsy","status":"RECRUITING","sponsor":"Gitte Moos Knudsen","startDate":"2022-02-18","conditions":"Epilepsy","enrollment":550},{"nctId":"NCT02100644","phase":"PHASE4","title":"Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-12","conditions":"Epilepsy","enrollment":33},{"nctId":"NCT01357902","phase":"PHASE1","title":"Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-18","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT00605371","phase":"PHASE1","title":"Bioequivalence and Food Effect of 250mg of Lamotrigine XR","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-15","conditions":"Epilepsy","enrollment":209},{"nctId":"NCT00068770","phase":"PHASE2","title":"Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2003-10","conditions":"Brain and Central Nervous System Tumors","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Standard lamotrigine"],"phase":"marketed","status":"active","brandName":"Standard dose lamotrigine","genericName":"Standard dose lamotrigine","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability. Used for Epilepsy (adjunctive and monotherapy), Bipolar disorder maintenance treatment, Lennox-Gastaut syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}